CARM Stock Overview
A clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Carisma Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.33 |
| 52 Week High | US$9.77 |
| 52 Week Low | US$1.24 |
| Beta | 0 |
| 1 Month Change | -18.40% |
| 3 Month Change | -48.65% |
| 1 Year Change | -79.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.76% |
Recent News & Updates
Recent updates
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results
May 12
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%
Apr 19We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop
Jan 21The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%
Dec 07Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)
Nov 12Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Shareholder Returns
| CARM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | -0.3% | -0.6% |
| 1Y | -79.2% | 5.4% | 22.3% |
Return vs Industry: CARM underperformed the US Biotechs industry which returned 4.7% over the past year.
Return vs Market: CARM underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| CARM volatility | |
|---|---|
| CARM Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CARM's share price has been volatile over the past 3 months.
Volatility Over Time: CARM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 107 | Steve Kelly | www.carismatx.com |
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
Carisma Therapeutics, Inc. Fundamentals Summary
| CARM fundamental statistics | |
|---|---|
| Market cap | US$54.42m |
| Earnings (TTM) | -US$81.21m |
| Revenue (TTM) | US$15.07m |
3.7x
P/S Ratio-0.7x
P/E RatioIs CARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CARM income statement (TTM) | |
|---|---|
| Revenue | US$15.07m |
| Cost of Revenue | US$74.95m |
| Gross Profit | -US$59.87m |
| Other Expenses | US$21.34m |
| Earnings | -US$81.21m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.95 |
| Gross Margin | -397.22% |
| Net Profit Margin | -538.81% |
| Debt/Equity Ratio | 0% |
How did CARM perform over the long term?
See historical performance and comparison